<DOC>
	<DOCNO>NCT00725543</DOCNO>
	<brief_summary>This prospective , open-label , 1-arm , multicenter observational study determine dose time span Remicade infusion ankylose spondylitis ( AS ) .</brief_summary>
	<brief_title>Investigation 9 Consecutive Remicade Infusions Ankylosing Spondylitis Austria ( Study P04044 ) ( COMPLETED )</brief_title>
	<detailed_description>This study population choose non-probability sample .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Subjects ankylose spondylitis severe axial symptom elevate serological marker inflammatory activity . Subjects tuberculosis severe infection sepsis , abscess , opportunistic infection . Subjects moderate severe heart failure ( New York Heart Association ( NYHA ) class III/IV ) . Subjects history hypersensitivity Remicade murine protein , excipients .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>